These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Genetic and genomic markers of anti-TNF treatment response in rheumatoid arthritis. Oliver J; Plant D; Webster AP; Barton A Biomark Med; 2015; 9(6):499-512. PubMed ID: 26079957 [TBL] [Abstract][Full Text] [Related]
3. Application of omics in predicting anti-TNF efficacy in rheumatoid arthritis. Xie X; Li F; Li S; Tian J; Chen JW; Du JF; Mao N; Chen J Clin Rheumatol; 2018 Jan; 37(1):13-23. PubMed ID: 28600618 [TBL] [Abstract][Full Text] [Related]
4. The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis. Camussi G; Lupia E Drugs; 1998 May; 55(5):613-20. PubMed ID: 9585859 [TBL] [Abstract][Full Text] [Related]
5. Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs. Narvaez J; Díaz-Torné C; Ruiz JM; Hernandez MV; Torrente-Segarra V; Ros S; Rodriguez de la Serna A; Díaz-López C; Sanmartí R; Nolla JM Clin Exp Rheumatol; 2011; 29(6):991-7. PubMed ID: 22133052 [TBL] [Abstract][Full Text] [Related]
6. GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis. Acosta-Colman I; Palau N; Tornero J; Fernández-Nebro A; Blanco F; González-Alvaro I; Cañete JD; Maymó J; Ballina J; Fernández-Gutiérrez B; Olivé A; Corominas H; Erra A; Canela-Xandri O; Alonso A; López Lasanta M; Tortosa R; Julià A; Marsal S Pharmacogenomics; 2013 May; 14(7):727-34. PubMed ID: 23651021 [TBL] [Abstract][Full Text] [Related]
7. Association of anti-CCP positivity and carriage of TNFRII susceptibility variant with anti-TNF-α response in rheumatoid arthritis. Vasilopoulos Y; Bagiatis V; Stamatopoulou D; Zisopoulos D; Alexiou I; Sarafidou T; Settas L; Sakkas L; Mamouris Z Clin Exp Rheumatol; 2011; 29(4):701-4. PubMed ID: 21813066 [TBL] [Abstract][Full Text] [Related]
8. Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis. Lee YH; Bae SC Rheumatol Int; 2016 Jun; 36(6):837-44. PubMed ID: 27074847 [TBL] [Abstract][Full Text] [Related]
9. Can Cyclosporine-A associated to methotrexate maintain remission induced by anti-TNF agents in rheumatoid arthritis patients? (Cynar pilot study). Migliore A; Bizzi E; Massafra U; Vacca F; Martin Martin LS; Ferlito C; Podestà E; Granata M; Laganà B Int J Immunopathol Pharmacol; 2010; 23(3):783-90. PubMed ID: 20943048 [TBL] [Abstract][Full Text] [Related]
10. PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis. Julià A; Rodríguez J; Fernández-Sueiro JL; Gratacós J; Queiró R; Montilla C; Torre-Alonso JC; Pérez-Venegas JJ; Manrique-Arija S; Muñoz-Fernández S; González C; Roig D; Zarco P; Erra A; Castañeda S; García A; Salvador G; Díaz-Torne C; Blanco R; Domínguez AW; Mosquera JA; Vela P; Tornero J; Sánchez-Fernández S; Corominas H; Ramírez J; Avila G; Alonso A; Tortosa R; López-Lasanta M; Cañete JD; Marsal S Pharmacogenomics; 2014 Nov; 15(14):1763-1769. PubMed ID: 25493569 [TBL] [Abstract][Full Text] [Related]
11. Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden. Raaschou P; Simard JF; Asker Hagelberg C; Askling J; BMJ; 2016 Jan; 352():i262. PubMed ID: 26823527 [TBL] [Abstract][Full Text] [Related]
12. Confirmation of an IRAK3 polymorphism as a genetic marker predicting response to anti-TNF treatment in rheumatoid arthritis. Sode J; Vogel U; Bank S; Andersen PS; Hetland ML; Locht H; Heegaard NHH; Andersen V Pharmacogenomics J; 2018 Jan; 18(1):81-86. PubMed ID: 27698401 [TBL] [Abstract][Full Text] [Related]
13. High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study. Takeuchi T; Miyasaka N; Inui T; Yano T; Yoshinari T; Abe T; Koike T Arthritis Res Ther; 2017 Sep; 19(1):194. PubMed ID: 28865493 [TBL] [Abstract][Full Text] [Related]
14. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. Bongartz T; Sutton AJ; Sweeting MJ; Buchan I; Matteson EL; Montori V JAMA; 2006 May; 295(19):2275-85. PubMed ID: 16705109 [TBL] [Abstract][Full Text] [Related]
15. Power of crowdsourcing: novel methods of data collection in psoriasis and psoriatic arthritis. Armstrong AW; Harskamp CT; Cheeney S; Wu J; Schupp CW J Am Acad Dermatol; 2012 Dec; 67(6):1273-1281.e9. PubMed ID: 22818792 [TBL] [Abstract][Full Text] [Related]
16. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Hyrich KL; Watson KD; Silman AJ; Symmons DP; Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046 [TBL] [Abstract][Full Text] [Related]
17. Variations in the metabolome in response to disease activity of rheumatoid arthritis. Tatar Z; Migne C; Petera M; Gaudin P; Lequerre T; Marotte H; Tebib J; Pujos Guillot E; Soubrier M BMC Musculoskelet Disord; 2016 Aug; 17(1):353. PubMed ID: 27549132 [TBL] [Abstract][Full Text] [Related]
18. Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis. Wampler Muskardin T; Vashisht P; Dorschner JM; Jensen MA; Chrabot BS; Kern M; Curtis JR; Danila MI; Cofield SS; Shadick N; Nigrovic PA; St Clair EW; Bingham CO; Furie R; Robinson W; Genovese M; Striebich CC; O'Dell JR; Thiele GM; Moreland LW; Levesque M; Bridges SL; Gregersen PK; Niewold TB Ann Rheum Dis; 2016 Oct; 75(10):1757-62. PubMed ID: 26546586 [TBL] [Abstract][Full Text] [Related]